Neuroscience (NEUROS) Research Group, Neurovitae Center for Neuroscience, Institute of Translational Medicine (IMT), Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia.
Laboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, Chile.
PLoS One. 2023 Apr 3;18(4):e0283845. doi: 10.1371/journal.pone.0283845. eCollection 2023.
Ocular toxoplasmosis (OT) is caused by the parasite Toxoplasma gondii. OT is the leading cause of posterior uveitis globally; it is a recurrent disease that may result in visual impairment and blindness. This systematic review and meta-analysis aim to summarize and evaluate the risk factors for recurrences, visual impairment, and blindness described in the literature worldwide.
We performed a systematic literature search in PubMed, Embase, VHL, Cochrane Library, Scopus, and DANS EASY Archive. All studies reporting patients with clinically and serologically confirmed OT presenting any clinical or paraclinical factor influencing recurrences, visual impairment, and blindness were included. Studies presenting secondary data, case reports, and case series were excluded. An initial selection was made by title and abstract, and then the studies were reviewed by full text where the eligible studies were selected. Then, the risk of bias was assessed through validated tools. Data were extracted using a validated extraction format. Qualitative synthesis and quantitative analysis were done. This study was registered on PROSPERO (CRD42022327836).
Seventy two studies met the inclusion criteria. Fifty-three were summarized in the qualitative synthesis in three sections: clinical and environmental factors, parasite and host factors, and treatment-related factors. Of the 72 articles, 39 were included in the meta-analysis, of which 14 were conducted in South America, 13 in Europe, four in Asia, three multinational, two in North America and Central America, respectively, and only one in Africa. A total of 4,200 patients with OT were analyzed, mean age ranged from 7.3 to 65.1 year of age, with similar distribution by sex. The frequency of recurrences in patients with OT was 49% (95% CI 40%-58%), being more frequent in the South American population than in Europeans. Additionally, visual impairment was presented in 35% (95% CI 25%-48%) and blindness in 20% (95% CI 13%-30%) of eyes, with a similar predominance in South Americans than in Europeans. On the other hand, having lesions near the macula or adjacent to the optic nerve had an OR of 4.83 (95% CI; 2.72-8.59) for blindness, similar to having more than one recurrence that had an OR of 3.18 (95% CI; 1.59-6.38). Finally, the prophylactic therapy with Trimethoprim/Sulfamethoxazole versus the placebo showed a protective factor of 83% during the first year and 87% in the second year after treatment.
Our Systematic Review showed that clinical factors such as being older than 40 years, patients with de novo OT lesions or with less than one year after the first episode, macular area involvement, lesions greater than 1 disc diameter, congenital toxoplasmosis, and bilateral compromise had more risk of recurrences. Also, environmental and parasite factors such as precipitations, geographical region where the infection is acquired, and more virulent strains confer greater risk of recurrences. Therefore, patients with the above mentioned clinical, environmental, and parasite factors could benefit from using prophylactic therapy.
眼弓形体病(OT)是由寄生虫弓形体引起的。OT 是全球后葡萄膜炎的主要原因;它是一种复发性疾病,可能导致视力损害和失明。本系统评价和荟萃分析旨在总结和评估全球文献中描述的复发性、视力损害和失明的风险因素。
我们在 PubMed、Embase、VHL、Cochrane 图书馆、Scopus 和 DANS EASY 档案中进行了系统的文献检索。所有报告有临床和血清学确诊的 OT 患者出现任何影响复发、视力损害和失明的临床或临床前因素的研究均被纳入。报告次要数据、病例报告和病例系列的研究被排除在外。通过标题和摘要进行初步选择,然后通过全文审查选择合格的研究。然后,使用经过验证的工具评估偏倚风险。使用经过验证的提取格式提取数据。进行定性综合和定量分析。本研究在 PROSPERO(CRD42022327836)上注册。
72 项研究符合纳入标准。53 项研究在三个部分进行了定性综合:临床和环境因素、寄生虫和宿主因素以及治疗相关因素。在 72 篇文章中,有 39 篇被纳入荟萃分析,其中 14 篇在南美洲进行,13 篇在欧洲进行,4 篇在亚洲进行,3 篇在多国进行,分别在北美和中美洲进行,只有 1 篇在非洲进行。共分析了 4200 例 OT 患者,平均年龄为 7.3 至 65.1 岁,性别分布相似。OT 患者的复发频率为 49%(95%CI 40%-58%),南美人群比欧洲人群更频繁。此外,35%(95%CI 25%-48%)的眼睛出现视力损害,20%(95%CI 13%-30%)的眼睛出现失明,南美人群与欧洲人群的比例相似。另一方面,靠近黄斑或视神经附近的病变与失明的比值比为 4.83(95%CI;2.72-8.59),与有一次以上复发的比值比为 3.18(95%CI;1.59-6.38)相似。最后,在治疗后第一年和第二年,使用复方新诺明与安慰剂相比,预防性治疗的保护因子分别为 83%和 87%。
我们的系统综述表明,临床因素如年龄大于 40 岁、新出现的 OT 病变或首次发作后不到一年、黄斑区受累、病变大于 1 个视盘直径、先天性弓形体病和双侧受累的患者复发风险更高。此外,环境和寄生虫因素,如降水、感染发生的地理区域和更具毒力的菌株,都会增加复发的风险。因此,具有上述临床、环境和寄生虫因素的患者可能受益于预防性治疗。